This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Medifast Announces Partnership With The V Foundation For Cancer Research













OWINGS MILLS, Md., Feb. 11, 2014 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs announced today its partnership with The V Foundation for Cancer Research, one of the nation's leading cancer research funding organizations. As part of this multi-faceted partnership with The V Foundation, Medifast will fund research grants that explore the link between obesity and cancer and the impact of healthy living on preventing cancer-related diseases.

The partnership will kick off with the Medifast Slam Dunk Contest. Medifast will match clients' contributions to The V Foundation, which can be made at MedifastNow.com and at corporate Medifast Weight Control Centers from February 10 to March 10, 2014.  Additional events will be announced throughout the year with support from each of Medifast's distribution channels.

"Partnering with an outstanding organization like The V Foundation for Cancer Research is an extremely proud moment for Medifast, and we are humbled by the opportunity to help make a difference in a way that is very personal to us," said Mike MacDonald, Chairman and Chief Executive Officer of Medifast. "Our corporate contributions, event partnerships, and client contributions throughout the year combined with our matched funds will help The V Foundation continue their essential and urgent work in finding cures for cancer and builds upon our mission to support healthy living."

"We cannot express how grateful we are that Medifast is making The V Foundation for Cancer Research a priority," said Susan Braun, CEO of The V Foundation for Cancer Research. "This important partnership with Medifast provides critical support as we work to put an end to cancer. This is a natural fit for our organization, and we are excited to do great work together."

The first in a series of events, the Slam Dunk Contest commences on February 10 and runs through March 10, 2014.  No purchase, payment, or donation of any kind is necessary to enter or win the contest.  Additional terms and conditions apply. Please see MedifastNow.com for Official Contest Rules. Contestants may voluntarily donate to The V Foundation for Cancer Research at the time of entry into the contest. The Grand Prize package includes two (2) round-trip air transportation tickets, five (5) nights lodging, two (2) tickets to the Men's NCAA Semi-Finals and Championship college basketball games, and two (2) tickets to the Slam Dunk Concert with Darius Rucker at Gilley's in Dallas, TX.  The Total package is valued at approximately $5000.   

All received donations directly benefit The V Foundation for Cancer Research, which has funded more than $115 million in cancer research grants nationwide, with 100 percent of cash donations funding cancer research.

MED-G

About Medifast:

Medifast (NYSE: MED) is the leading easy-to-use, clinically proven, portion-controlled weight-loss program. The company sells its products and programs via four unique distribution channels: 1) the Web and national call centers, 2) the Take Shape For Life personal coaching division, 3) Medifast Weight Control Centers, and 4) a national network of physicians. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, log onto  www.MedifastNow.com.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs